E6-positive lung cancer patients with lower expression of miR-184 and higher expression of Bcl-2 tumors or patients with E6-positive/low-miR-184, low-miR-184/high-Bcl-2, E6-positive/high-Bcl-2 tumors have shown less sensitivity towards cisplatin (Tung et al., 2016). This evidence concerns the gene BCL2 and lung carcinoma.